Question

In: Accounting

Problem 16-5 Amy Dyken, controller at Ivanhoe Pharmaceutical Industries, a public company, is currently preparing the...

Problem 16-5

Amy Dyken, controller at Ivanhoe Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Ivanhoe’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2017.

IVANHOE PHARMACEUTICAL INDUSTRIES
SELECTED BALANCE SHEET
INFORMATION
JUNE 30, 2017

Long-term debt
   Notes payable, 11%

$1,010,000

   8% convertible bonds payable

5,050,000

   11% bonds payable

5,950,000

     Total long-term debt

$12,010,000

Shareholders’ equity
   Preferred stock, 6% cumulative, $50 par value, 105,000 shares authorized, 26,250 shares issued and outstanding

$1,312,500

   Common stock, $1 par, 9,800,000 shares authorized, 980,000 shares issued and outstanding

980,000

   Additional paid-in capital

3,940,000

   Retained earnings

5,910,000

     Total shareholders’ equity

$12,142,500


The following transactions have also occurred at Ivanhoe.

1. Options were granted on July 1, 2016, to purchase 200,000 shares at $15 per share. Although no options were exercised during fiscal year 2017, the average price per common share during fiscal year 2017 was $20 per share.
2. Each bond was issued at face value. The 8% convertible bonds will convert into common stock at 50 shares per $1,000 bond. The bonds are exercisable after 5 years and were issued in fiscal year 2016.
3. The preferred stock was issued in 2016.
4. There are no preferred dividends in arrears; however, preferred dividends were not declared in fiscal year 2017.
5. The 980,000 shares of common stock were outstanding for the entire 2017 fiscal year.
6. Net income for fiscal year 2017 was $1,520,000, and the average income tax rate is 40%.


For the fiscal year ended June 30, 2017, calculate the following for Ivanhoe Pharmaceutical Industries. (Round answers to 2 decimal places, e.g. $2.45.)

(a) Basic earnings per share.


(b) Diluted earnings per share
.

Solutions

Expert Solution

Ques 1
Basic EPS
=Net income-preferrence dividends / weighted average common shares outstanding
Net income 1520000
Less:preference dividend 78750
1312500*0.06
earnings available to common stockholders 1441250
Weighted average common shares 980000
EPS-Basic $                                  1.47 per share
1441250/980000
Ques 2
potential dilutive securities are the convertible bonds and stock options
the interest on bonds 404000
5050000*0.08
Less:taxes 161600
After tax amount 242400
Bonds converted to common stock 252500 additional shares
5050000/100050
Stock options
200000shares issued*15option price 3000000
3000000total proceeds/20averagemarket price 150000 shares
200000shares issued-150000shares assumed repurchased 50000 icemental shares
So for diluted EPS we have
Net income 1520000
less:preferrence dividend -78750
Add:interest saving 242400
earnings available to common stockholders 1683650
Weighted average no. of shares
original 980000
Add:new shares issued
bonds 252500
stock option 50000
total 1282500
Diluted EPS
1683650/1282500 $                                  1.31 PER share

Related Solutions

Problem 16-5 Amy Dyken, controller at Kingbird Pharmaceutical Industries, a public company, is currently preparing the...
Problem 16-5 Amy Dyken, controller at Kingbird Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Kingbird’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2017. KINGBIRD PHARMACEUTICAL INDUSTRIES SELECTED BALANCE SHEET INFORMATION JUNE 30, 2017 Long-term debt Notes payable, 9% $1,000,000 8% convertible bonds payable 4,910,000 9% bonds payable 6,080,000 Total long-term debt $11,990,000 Shareholders’ equity Preferred stock, 7% cumulative,...
Problem 16-5 Amy Dyken, controller at Buffalo Pharmaceutical Industries, a public company, is currently preparing the...
Problem 16-5 Amy Dyken, controller at Buffalo Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Buffalo’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2017. BUFFALO PHARMACEUTICAL INDUSTRIES SELECTED BALANCE SHEET INFORMATION JUNE 30, 2017 Long-term debt Notes payable, 10% $1,000,000 8% convertible bonds payable 5,080,000 10% bonds payable 5,940,000 Total long-term debt $12,020,000 Shareholders’ equity Preferred stock, 6% cumulative,...
Amy Dyken, controller at Sheridan Pharmaceutical Industries, a public company, is currently preparing the calculation for...
Amy Dyken, controller at Sheridan Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Sheridan’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Sheridan Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt Notes payable, 10% $1,010,000 9% convertible bonds payable 5,090,000 10% bonds payable 6,060,000 Total long-term debt $12,160,000 Shareholders’ equity Preferred stock, 6% cumulative, $50 par...
Amy Dyken, controller at Marigold Pharmaceutical Industries, a public company, is currently preparing the calculation for...
Amy Dyken, controller at Marigold Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Marigold’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Marigold Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt    Notes payable, 11% $980,000    8% convertible bonds payable 5,030,000    11% bonds payable 6,100,000      Total long-term debt $12,110,000 Shareholders’ equity    Preferred stock, 6% cumulative, $50 par...
Amy Dyken, controller at Waterway Pharmaceutical Industries, a public company, is currently preparing the calculation for...
Amy Dyken, controller at Waterway Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Waterway’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Waterway Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt       Notes payable, 10% $990,000 8% convertible bonds payable       5,030,000 10% bonds payable 5,880,000 Total long-term debt $11,900,000         Shareholders’ equity       Preferred...
Question 4 Amy Dyken, controller at Marigold Pharmaceutical Industries, a public company, is currently preparing the...
Question 4 Amy Dyken, controller at Marigold Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Marigold’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Marigold Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt Notes payable, 10% $1,020,000 8% convertible bonds payable 5,080,000 10% bonds payable 6,110,000 Total long-term debt $12,210,000 Shareholders’ equity Preferred stock, 6% cumulative,...
Problem 1: A company is going public at $16 and will use the ticker XYZ. The...
Problem 1: A company is going public at $16 and will use the ticker XYZ. The underwriters will charge a 7 percent spread. The company is issuing 20 million shares, and insiders will continue to hold an additional 40 million shares that will not be part of the IPO. The company will also pay $1 million of audit fees, $2 million of legal fees, and $500,000 of printing fees. The stock closes the first day at $19. The company in...
Eye Trendy Corporation is a distributor of frames for sunglasses. The company’s controller is currently preparing...
Eye Trendy Corporation is a distributor of frames for sunglasses. The company’s controller is currently preparing a budget for the third quarter of the year. The following information is from company’s financial records: Projected Sales July 3,120 units August 2,000 units September 2,640 units October 3,000 units • Selling price is RM25 per unit • Collections from customers are normally 70 per cent in the month of sale, 20 per cent in the month following sale, and 9 per cent...
Oman Pharmaceutical Industries Co. (OPP) is one of the fastest growing pharmaceutical company in GCC. It...
Oman Pharmaceutical Industries Co. (OPP) is one of the fastest growing pharmaceutical company in GCC. It manufactures four joint products Azithromycin, Clarithromycin, Levofloxacin and Moxifloxacin from a chemical process. After further processing, the company sells Azithromycin, Clarithromycin, Levofloxacin and Moxifloxacin at a price of RO 20, RO 24, RO 16 and RO 12 and estimates a profit of 17.5%, 12.5%, 12.5% and 15% respectively. The costs incurred till the split- off point are RO 39,000. The output achieved at the...
Victor Mineli, the new controller of Ivanhoe Company, has reviewed the expected useful lives and salvage...
Victor Mineli, the new controller of Ivanhoe Company, has reviewed the expected useful lives and salvage values of selected depreciable assets at the beginning of 2017. Here are his findings: Type of Asset Date Acquired Cost Accumulated Depreciation, Jan. 1, 2017 Useful Life (in years) Salvage Value Old Proposed Old Proposed Building Jan. 1, 2009 $857,000 $159,100 40 48 $61,500 $35,600 Warehouse Jan. 1, 2012 129,500 24,960 25 20 4,700 5,300 All assets are depreciated by the straight-line method. Ivanhoe...
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT